Cardiome Announces C$30 Million Primary and Secondary Common Share Offering

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE
UNITED STATES/

VANCOUVER, Feb. 20, 2014 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME /
TSX: COM) ("Cardiome") and CarCor Investment Holdings LLC ("CarCor"), the shareholder from which Cardiome purchased Correvio LLC, are
pleased to announce that they have entered into an agreement with a
group of underwriters led by Canaccord Genuity Corp. (the "Underwriters") for the sale, on a bought deal basis, of 1,500,000 common shares from
Cardiome for gross proceeds of C$15 million (the "Primary Offering") and 1,500,000 common shares in a secondary offering from Carcor for
gross proceeds of C$15 million (the "Secondary Offering") both at C$10.00 per common share, for a combined offering of C$30
million (collectively, the "Offering").

The Company and CarCor have granted the Underwriters an over-allotment
option to purchase, pro rata from each of Cardiome and CarCor, up to an
additional 15% of the Offering (representing an aggregate of 450,000
common shares) on the same terms and conditions, exercisable in whole
or in part at any time following closing of the Offering for a period
of 30 days.

Cardiome currently intends to use the net proceeds of the Primary
Offering for working capital and general corporate purposes, including
to fund expansion of our sales and marketing efforts for BRINAVESS® and
AGGRASTAT® in Europe and other parts of the world, for funding clinical
development and regulatory costs of vernakalant (IV) and vernakalant
(oral), and for advancement of Cardiome's business objectives. Cardiome
will not receive any proceeds from the Secondary Offering.

After giving effect to the Offering, but before giving effect to the
exercise of the over-allotment options, CarCor will own 981,596 common
shares of the Company, representing a 5.9% fully diluted interest.
Assuming full exercise of the over-allotment option, CarCor would own a
4.5% fully diluted interest in Cardiome.

Closing of the Offering is expected to occur on or about March 11, 2014
and is subject to certain conditions and approvals including, but not
limited to, the receipt of approval by the Toronto Stock Exchange.

The common shares will be offered under a short form prospectus to be
filed in each of the provinces of Canada, except Québec.

This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of Cardiome in the
United States or to, or for the account or benefit of U.S. persons (as
defined in Regulation S under the U.S. Securities Act of 1933, as
amended (the "U.S. Securities Act"). The common shares described in this press release have not been and
will not be registered under the U.S. Securities Act, or the securities
laws of any state and may not be offered, sold or delivered in the
United States or to, or for the account or benefit of U.S. persons,
absent an exemption from registration.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to
the development and commercialization of cardiovascular therapies that
will improve the quality of life and health of patients suffering from
heart disease. Cardiome has two marketed, in-hospital, cardiology
products, BRINAVESS® (vernakalant IV), approved in Europe and other
territories for the rapid conversion of recent onset atrial
fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl)
a reversible GP IIb/IIIa inhibitor indicated for use in Acute Coronary
Syndrome patients.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto
Stock Exchange (COM).

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
"believe", "may", "plan", "will", "estimate", "continue", "anticipate",
"intend", "expect" and similar expressions. Forward- looking
statements in this news release include statements regarding the
intended use of proceeds from the Primary Offering and the anticipated
closing date of the offering. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause
the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by
such forward-looking statements. Many such known risks, uncertainties
and other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among others,
the following: general economic and business conditions in the United
States, Canada, Europe, and the other regions in which we operate; not
receiving the regulatory approvals, including the further approvals
that may be sought from securities regulatory authorities, on the
timelines required or at all, that the prevailing market price of our
securities may make sales under the prospectus supplement unattractive
to Cardiome as well as those factors discussed in or referred to under
the heading "Risk Factors" in Cardiome's Annual Report on Form 20-F for
the year ended December 31, 2012 which is available under Cardiome's
profile on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Given these risks, uncertainties and factors, you are cautioned not to
place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary
statement. All forward-looking statements and information made herein
are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by law.